Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia.
Standard
Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia. / Lugthart, Sanne; Cheok, Meyling H; Boer, den; Monique, L; Yang, Wenjian; Holleman, Amy; Cheng, Cheng; Pui, Ching-Hon; Janka-Schaub, Gritta; Janka-Schaub, Gritta E; Pieters, Rob; Evans, William E.
In: CANCER CELL, Vol. 7, No. 4, 4, 2005, p. 375-386.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia.
AU - Lugthart, Sanne
AU - Cheok, Meyling H
AU - Boer, den
AU - Monique, L
AU - Yang, Wenjian
AU - Holleman, Amy
AU - Cheng, Cheng
AU - Pui, Ching-Hon
AU - Janka-Schaub, Gritta
AU - Janka-Schaub, Gritta E
AU - Pieters, Rob
AU - Evans, William E
PY - 2005
Y1 - 2005
N2 - Acute lymphoblastic leukemia (ALL) can be cured with combination chemotherapy in over 75% of children, but the cause of treatment failure in the remaining patients is unknown. We determined the sensitivity of ALL cells to individual antileukemic agents in 441 patients and used a genome-wide approach to identify 45 genes differentially expressed in ALL exhibiting crossresistance to prednisolone, vincristine, asparaginase, and daunorubicin. We also identified a distinct phenotype of discordant resistance to asparaginase and vincristine and 139 genes whose expression was associated with this novel phenotype. The expression of these genes discriminated treatment outcome in two independent patient populations, identifying a subset of patients with a markedly inferior outcome (37% +/- 13% 5 year DFS).
AB - Acute lymphoblastic leukemia (ALL) can be cured with combination chemotherapy in over 75% of children, but the cause of treatment failure in the remaining patients is unknown. We determined the sensitivity of ALL cells to individual antileukemic agents in 441 patients and used a genome-wide approach to identify 45 genes differentially expressed in ALL exhibiting crossresistance to prednisolone, vincristine, asparaginase, and daunorubicin. We also identified a distinct phenotype of discordant resistance to asparaginase and vincristine and 139 genes whose expression was associated with this novel phenotype. The expression of these genes discriminated treatment outcome in two independent patient populations, identifying a subset of patients with a markedly inferior outcome (37% +/- 13% 5 year DFS).
M3 - SCORING: Zeitschriftenaufsatz
VL - 7
SP - 375
EP - 386
JO - CANCER CELL
JF - CANCER CELL
SN - 1535-6108
IS - 4
M1 - 4
ER -